Spectral AI (MDAI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 Apr, 2026Executive summary
The annual meeting is scheduled for May 29, 2026, both in-person and virtually, with voting on key proposals and director elections.
Proxy materials are distributed via internet under SEC's "notice and access" rules, with options for paper copies.
Stockholders of record as of April 1, 2026, are eligible to vote, with 31,823,985 shares outstanding.
Voting matters and shareholder proposals
Election of five directors to serve until the next annual meeting.
Ratification of Forvis Mazars, LLP as independent auditor for 2026.
Authorization for reservation and issuance of up to 8,000,000 shares to Hudson Bay under a securities purchase agreement, subject to Nasdaq rules.
Other business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Board consists of five directors, with a majority deemed independent under Nasdaq rules.
Board committees include Audit, Compensation, Nominating and Corporate Governance, Science and Technology, and Executive Committees.
Leadership structure changed in February 2026, appointing Vincent Capone as CEO and dissolving the Office of the Chairman.
Corporate governance guidelines, code of conduct, and insider trading policy are in place and available on the company website.
Latest events from Spectral AI
- FDA clearance enables 2026 commercial launch; net loss narrows, cash at $14M, revenue still government-based.MDAI
Q2 2026 - Q1 2026 revenue fell to $4.0M, net loss was $3.4M, and BARDA funding advanced DeepView.MDAI
Q1 2026 - Director elections, auditor ratification, and share issuance to Hudson Bay Master Fund Ltd. on agenda.MDAI
Proxy filing - Shareholders will vote on director elections, auditor ratification, and a significant share issuance.MDAI
Proxy filing - 2025 net loss narrowed, cash rose to $15.4M, and 2026 revenue is forecast at $18.5M.MDAI
Q4 2025 - Q3 revenue up 138% to $8.2M, margins improved, and FDA submission and spin-off plans advance.MDAI
Q3 2024 - AI-driven wound care system nears FDA submission, with UK pilots and strong funding support.MDAI
H.C. Wainwright 26th Annual Global Investment Conference 2024 - Q2 revenue up 76% year-over-year; UK commercialization and FDA submission on track.MDAI
Q2 2024 - Record R&D revenue and clinical validation position DeepView for 2025 FDA submission.MDAI
Q4 2024